Drug intelligence / Profile preview

TQ-1005

Development stage: Preclinical
Lead developer: TQ Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

TQ-1005 is an experimental *in vivo* CAR-T cell therapy being developed by TQ Therapeutics for longevity-related indications. Utilizing the company's proprietary EXiVO platform, the therapy is designed to generate chimeric antigen receptor (CAR) T cells directly within the patient's body to target and eliminate CD57-expressing cells. CD57 is a carbohydrate epitope often used as a marker for senescent or terminally differentiated cells, which accumulate with age and contribute to chronic inflammation and tissue dysfunction. By clearing these senescent cells, TQ-1005 aims to promote healthy aging and extend longevity. The program is currently in the preclinical stage of development.

Beyond the preview

Go deeper on TQ-1005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQ-1005.

Explore the full profile